Market Opportunities

Obesity

Obesity prevalence has nearly tripled since 1975 and today is pandemic
- Affecting one third of the world population
- Responsible for more than 10% of US health care costs
- In 2016, more than 1.9 billion adults were overweight; of these over 650 million were obese
The Economic burden of obesity is large:

Current medical treatments:
- have poor benefit-to-risk profiles with unpleasant side effects
- fail to achieve long-term therapeutic results
- do not meet patients’ expectations
- often are not covered by health insurance plans

The US Weight Loss and Diet Control market was worth $66 Billion in 2017
A safe and effective (>10% weight loss) drug should garner up to $20 Billion in annual revenues

NAFLD

Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population with a range from 13.5% in Africa to 31.8% in the Middle East.
- Lifetime costs of all NASH patients in the United States in 2017 will be $222.6 billion, and the cost of the advanced NASH population will be $95.4 billion.
NAFLD prevalence can be inferred from the prevalence of obesity and diabetes
Prevalence of liver steatosis is 76% in obese patients
There is currently no approved drug for NAFLD/NASH
The NASH market is expected to reach $21 billion globally, by 2025 (www.alliedmarketresearch.com)

Investment Highlights

Target Fat Accumulation and related Metabolic Diseases with high unmet medical needs: The Obesity and Diabetes (Diabesity) and Nonalcoholic fatty liver disease (NAFLD) pandemics
Focus on Oligonucleotide Therapeutics (ONTs) microRNA analogs which increase lipid oxidation, insulin sensitivity, mitochondrial activity and energy expenditure
Convenient self-local administration of drug to increase compliance

Target Product Profile